Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 6/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2554986 | 0.85 | KDM4E (0.45) | KDM4ESMN1; SMN2KMT2AALDH1A1HRH3 | |
| SCHEMBL19211675 | 0.83 | CHKA (0.40) | KDM4EALDH1A1HRH3MTNR1BTDP1 | |
| SCHEMBL29953357 | 0.81 | KDM4E (0.64) | KDM4ESMN1; SMN2ALDH1A1HRH3 | |
| SCHEMBL18704973 | 0.81 | KDM4E (0.64) | KDM4ESMN1; SMN2ALDH1A1SOS1TDP1 | |
| SCHEMBL15330847 | 0.81 | KDM4E (0.52) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL2562320 | 0.80 | KDM4E (0.47) | KDM4ESMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL20680179 | 0.79 | KDM4E (0.45) | KDM4ESMN1; SMN2ALDH1A1SOS1TDP1 | |
| SCHEMBL19211655 | 0.79 | CHKA (0.38) | KDM4EMEN1KMT2AATMALDH1A1 | |
| SCHEMBL428266 | 0.79 | CYP2A13 (0.56) | KDM4ESMN1; SMN2KMT2AALDH1A1TDP1 | |
| SCHEMBL30519205 | 0.78 | KDM4E (0.44) | KDM4ESMN1; SMN2ATMALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108884046-B | Chemical compounds as inhibitors of kinase activity | 葛兰素史克知识产权开发有限公司 | 2021-11-09 | — | — | CN | disclosed |
| US-10793559-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-06 | — | — | US | disclosed |
| US-10793559-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-10-06 | — | — | US | disclosed |
| EP-3414228-B1 | CHEMICAL COMPOUNDS AS INHIBITORS OF KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-03-18 | — | — | EP | disclosed |
| EP-3414228-B1 | CHEMICAL COMPOUNDS AS INHIBITORS OF KINASE ACTIVITY | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-03-18 | — | — | EP | disclosed |
| US-20200071311-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| US-20200071311-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-05 | — | — | US | disclosed |
| US-10457674-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-29 | — | — | US | disclosed |
| US-10457674-B2 | Chemical compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-10-29 | — | — | US | disclosed |
| US-20190040051-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-07 | — | — | US | disclosed |
| US-20190040051-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-02-07 | — | — | US | disclosed |
| EP-3414228-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF KINASE ACTIVITY | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017137535-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF KINASE ACTIVITY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017137535-A1 | CHEMICAL COMPOUNDS AS INHIBITORS OF KINASE ACTIVITY | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793559-B2 | Chemical compounds | PIK3CA, PIK3CD, PIK3C2B | KDM4E 1914/4885SMN1; SMN2 4722/4885MEN1 1141/4885 |
| US-20190040051-A1 | CHEMICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | KDM4E 1914/4885SMN1; SMN2 4722/4885MEN1 1141/4885 |
| US-20200071311-A1 | CHEMICAL COMPOUNDS | PIK3CA, PIK3CD, PIK3C2B | KDM4E 1914/4885SMN1; SMN2 4722/4885MEN1 1141/4885 |
| US-10457674-B2 | Chemical compounds | PIK3CA, PIK3CD, PIK3C2B | KDM4E 1914/4885SMN1; SMN2 4722/4885MEN1 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.